Loading…
BluefitMD was cited for selling compounded semaglutide and tirzepatide products with false or misleading claims in violation of the Federal Food, Drug, and Cosmetic Act (sections 502(a) and 502(bb)). The company's website falsely represented BluefitMD as the compounder of these drugs when it was not, and made claims implying the products were FDA-approved or evaluated for safety and effectiveness when compounded drugs are not subject to FDA approval. These misbranded products were offered for sale and delivery into interstate commerce through the company's website as of December 2025.